Impaired Infarct Healing in Atherosclerotic Mice With Ly-6C^hiMonocytosis

Objectives

The aim of this study was to test whether blood monocytosis in mice with atherosclerosis affects infarct healing.

Background

Monocytes are cellular protagonists of tissue repair, and their specific subtypes regulate the healing program after myocardial infarction (MI). Inflammatory Ly-6C^himonocytes dominate on Day 1 to Day 4 and digest damaged tissue; reparative Ly-6C^lomonocytes dominate on Day 5 to Day 10 and promote angiogenesis and scar formation. However, the monocyte repertoire is disturbed in atherosclerotic mice: Ly-6C^himonocytes expand selectively, which might disrupt the resolution of inflammation.

Methods

Ex vivo analysis of infarcts included flow cytometric monocyte enumeration, immunoactive staining, and quantitative polymerase chain reaction. To relate inflammatory activity to left ventricular remodeling, we used a combination of noninvasive fluorescence molecular tomography (FMT-CT) and physiologic imaging (magnetic resonance imaging).

Results

Five-day-old infarcts showed >10× more Ly-6C^himonocytes in atherosclerotic (apoE^−/−) mice compared with wild-type mice. The injured tissue in apoE^−/−mice also showed a more pronounced inflammatory gene expression profile (e.g., increased tumor necrosis factor-alpha and myeloperoxidase and decreased transforming growth factor-beta) and a higher abundance of proteases, which are associated with the activity of Ly-6C^himonocytes. The FMT-CT on Day 5 after MI showed higher proteolysis and phagocytosis in infarcts of atherosclerotic mice. Serial magnetic resonance imaging showed accelerated deterioration of ejection fraction between Day 1 and Day 21 after MI in apoE^−/−. Finally, we could recapitulate these features in wild-type mice with artificially induced Ly-6C^himonocytosis.

Conclusions

Ly-6C^himonocytosis disturbs resolution of inflammation in murine infarcts and consequently enhances left ventricular remodeling. These findings position monocyte subsets as potential therapeutic targets to augment tissue repair after infarction and to prevent post-MI heart failure.